BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AlloMap Molecular Expression Test: Post-marketing study completed enrollment

XDx completed enrollment of 40 patients in the open-label, U.S. post-marketing EIMAGE study to compare AlloMap Molecular Expression Test vs. endomyocardial biopsy surveillance to monitor patients 2-6 months after heart...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >